2. UroToday Home
  3. Tags

Acute Myeloid Leukemia (AML) Articles

Articles

  • TAT-10: Efficacy of Actinium-225-labeled Anti-CD33 Antibody in Acute Myeloid Leukemia Correlates with Peripheral Blast Count

    Kanazawa, Japan (UroToday.com) This study was conducted in two phases. Phase one had 18 relapsed and refractory acute myeloid leukemia (AML) patients. Patients were treated with a single infusion of Actimab-A, the company’s name for Ac-225 conjugated to the anti-CD33 monoclonal antibody lintuzumab. Doses ranged from 18.5 to 148 kBq/kg and post analysis determined a maximum dose of 111 kBq/kg. In the second trial (18 newly diagnosed patients), were treated with two equal doses at 14 days and 21 days. Total doses ranged from 37 to 148 kB/kq.
    Published June 21, 2017